Dermatology and Therapy (Sep 2024)
Secukinumab in the Treatment of Psoriasis: A Narrative Review on Early Treatment and Real-World Evidence
- Piergiorgio Malagoli,
- Paolo Dapavo,
- Paolo Amerio,
- Laura Atzori,
- Anna Balato,
- Federico Bardazzi,
- Luca Bianchi,
- Angelo Cattaneo,
- Andrea Chiricozzi,
- Maurizio Congedo,
- Maria Concetta Fargnoli,
- Claudia Giofrè,
- Paolo Gisondi,
- Claudio Guarneri,
- Serena Lembo,
- Francesco Loconsole,
- Giampiero Mazzocchetti,
- Santo Raffaele Mercuri,
- Pietro Morrone,
- Anna Maria Offidani,
- Giovanni Palazzo,
- Aurora Parodi,
- Giovanni Pellacani,
- Stefano Piaserico,
- Concetta Potenza,
- Francesca Prignano,
- Marco Romanelli,
- Paola Savoia,
- Luca Stingeni,
- Massimo Travaglini,
- Emanuele Trovato,
- Marina Venturini,
- Leonardo Zichichi,
- Antonio Costanzo
Affiliations
- Piergiorgio Malagoli
- Psocare Unit, IRCCS Policlinico San Donato
- Paolo Dapavo
- Clinica Dermatologica Universitaria di Torino, ASO Città della Salute e della Scienza
- Paolo Amerio
- Dermatology Unit, UOC Dermatologia, Università G.d’Annunzio
- Laura Atzori
- Dermatology Unit, Department Medical Sciences and Public Health, University of Cagliari
- Anna Balato
- Dermatology Unit, University of Campania Luigi Vanvitelli
- Federico Bardazzi
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Luca Bianchi
- Dermatology Unit, Fondazione Policlinico Tor Vergata
- Angelo Cattaneo
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
- Andrea Chiricozzi
- Dermatology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS
- Maurizio Congedo
- Dermatology Unit, Ospedale Vito Fazzi
- Maria Concetta Fargnoli
- Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila
- Claudia Giofrè
- U.O.C.di Dermatologia, Dermatology Unit, Azienda Ospedaliera Papardo
- Paolo Gisondi
- Sezione di Dermatologia e Venereologia, Dermatology Unit, Medicine Department, Università di Verona
- Claudio Guarneri
- Department of Biomedical, Dental Sciences and Morphofunctional Imaging, Section of Dermatology, University of Messina
- Serena Lembo
- Department of Medicine, Surgery and Dental Sciences “Scuola Medica Salernitana”, Università di Salerno
- Francesco Loconsole
- Dermatology Unit, Policlinico Consorziale
- Giampiero Mazzocchetti
- Dermatology Unit, UOSD Dermatologia, Ospedale “Santo Spirito”
- Santo Raffaele Mercuri
- Unit of Dermatology and Cosmetology, I.R.C.C.S. San Raffaele Hospital
- Pietro Morrone
- UOC Dermatologia, Dermatology Unit, Dipartimento Chirurgico Polispecialistico, Azienda Ospedaliera di Cosenza
- Anna Maria Offidani
- Department of Clinical and Molecular Sciences, Università Politecnica della Marche
- Giovanni Palazzo
- Ospedale Distrettuale di Tinchi, Azienda Sanitaria di Matera
- Aurora Parodi
- DiSSal Clinica Dermatologica, Università di Genova, Ospedale-policlinico San Martino IRCCS
- Giovanni Pellacani
- Dermatology, Department of Clinical Internistic Anaesthesiological and Cardiovascular Science, La Sapienza University of Rome
- Stefano Piaserico
- Dermatology Unit, Department of Medicine, University of Padova
- Concetta Potenza
- Dipartimento di Scienze e Biotecnologie Medico-Chirurgiche, Facoltà di Farmacia e Medicina, Sapienza Università di Roma - Polo Pontino
- Francesca Prignano
- Department of Health Science Section of Dermatology, University of Florence
- Marco Romanelli
- Dermatology Unit, Azienda Ospedaliero Universitaria Pisana, Ospedale Santa Chiara
- Paola Savoia
- Department of Health Science, University of Eastern Piedmont
- Luca Stingeni
- Dermatology Section, Department of Medicine and Surgery, University of Perugia
- Massimo Travaglini
- U.O.S.D. Dermatologica - Centro per la cura della psoriasi, Ospedale A. Perrino
- Emanuele Trovato
- Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena
- Marina Venturini
- Dermatology Department, University of Brescia and ASST Spedali Civili Hospital
- Leonardo Zichichi
- Dermatology Unit, UOC Dermatologia, Ospedale S A Antonio Abate, ASP Trapani
- Antonio Costanzo
- Dermatology Unit, Department of Biomedical Sciences, Humanitas University
- DOI
- https://doi.org/10.1007/s13555-024-01255-4
- Journal volume & issue
-
Vol. 14,
no. 10
pp. 2739 – 2757
Abstract
Abstract Psoriasis is a chronic, immune-mediated, inflammatory skin disease, associated with multiple comorbidities and psychological and psychiatric disorders. The quality of life of patients with this disease is severely compromised, especially in moderate-to-severe plaque psoriasis. Secukinumab, a fully humanized monoclonal antibody, was the first anti-interleukin (IL)-17 biologic approved for treating psoriasis. Secukinumab demonstrated long-lasting efficacy and a good safety profile in individuals with plaque psoriasis, and it is associated with an improvement in health-related quality of life. While there is evidence that early treatment with systemic therapy can affect disease progression and improve long-term outcomes in other autoimmune diseases, evidence is limited in psoriasis, especially in real-world settings. This review provides an overview of studies describing the effectiveness of secukinumab in the treatment of psoriasis summarizing the literature and focusing on real-world evidence and early intervention.
Keywords
